Walgreens Evaluating Potential Sale of Shields Health Specialty Pharmacy Business

Walgreens Boots (NASDAQ:WBA) is exploring strategic options for Shields Health Solutions, a specialty pharmacy business it acquired three years ago.

Could it fetch $4 billion or more in a potential sale? A recent Bloomberg report suggests so, citing sources familiar with the situation. Industry players and private equity firms are expected to show a keen interest in the unit.

While rumblings of a sale echo through the rumor mill, Walgreens has yet to commit to the decision, leaving the potential outcome on a knife’s edge.

Let’s rewind the tape to September 2022 when Walgreens Boots announced its plan to secure the remaining 30% stake of Shields Health Solutions for approximately $1.37 billion. That move followed the majority investment made in September 2021, costing Walgreens a cool $970 million.

Adding fuel to an already raging fire, reports suggest that amidst these developments, Walgreens is allegedly also mulling over the divestment of its UK Boots drugstore chain. Speculations abound regarding the chain’s valuation, estimated to hover around £7 billion ($8.8 billion).

Interestingly, this potential sale of the UK-based Boots operation comes hot on the heels of Walgreens sealing a deal with insurer Legal & General last November to shoulder the responsibility for the UK Boots pharmacy chain’s hefty £5 billion legacy pension plan.

With the annual meeting looming large, Walgreens (WBA) finds itself perched on a precipice, bracing for a high-stakes decision.